1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Vaccines Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Vaccines Market Country Analysis
6.2 North America Vaccines Market Revenue 2016-2027 (US$ Million)
6.3 North America Vaccines Market Forecast Analysis
7. North America Vaccines Market Analysis – by Technology
7.1 Recombinant Vaccines
- 7.1.1 Overview
- 7.1.2 Recombinant Vaccines: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.2 Conjugate Vaccines
- 7.2.1 Overview
- 7.2.2 Conjugate Vaccines: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.3 Live Attenuated Vaccines
- 7.3.1 Overview
- 7.3.2 Live Attenuated Vaccines: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.4 Inactivated and Subunit Vaccines
- 7.4.1 Overview
- 7.4.2 Inactivated and Subunit Vaccines: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.5 Toxoid Vaccines
- 7.5.1 Overview
- 7.5.2 Toxoid Vaccines: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
8. North America Vaccines Market Analysis – by Disease Indication
8.1 DTP
- 8.1.1 Overview
- 8.1.2 DTP: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.2 Influenza
- 8.2.1 Overview
- 8.2.2 Influenza: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.3 Hepatitis
- 8.3.1 Overview
- 8.3.2 Hepatitis: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.4 Respiratory Syncytial Virus
- 8.4.1 Overview
- 8.4.2 Respiratory Syncytial Virus: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.5 Other Diseases
- 8.5.1 Overview
- 8.5.2 Other Diseases: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
9. North America Vaccines Market Analysis – by Route of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
9.3 Other Routes of Administration
- 9.3.1 Overview
- 9.3.2 Other Routes of Administration: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
10. North America Vaccines Market Analysis – by Patient Type
10.1 Pediatric Patients
- 10.1.1 Overview
- 10.1.2 Pediatric Patients: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
10.2 Adult Patients
- 10.2.1 Overview
- 10.2.2 Adult Patients: North America Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)
11. North America Vaccines Market – North America (US, Canada, Mexico) Analysis
11.1 North America (US, Canada, Mexico)
- 11.1.1 North America (US, Canada, Mexico): North America Vaccines Market – Revenue
and Forecast to 2027 (US$ Million)
- 11.1.1.1 North America (US, Canada, Mexico):
North America Vaccines Market Breakdown, by Technology
- 11.1.1.2 North America (US, Canada, Mexico):
North America Vaccines Market Breakdown, by Disease Indication
- 11.1.1.3 North America (US, Canada, Mexico):
North America Vaccines Market Breakdown, by Route of Administration
- 11.1.1.4 North America (US, Canada, Mexico):
North America Vaccines Market Breakdown, by Patient Type
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 PFIZER INC
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Merck & Co., Inc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Sanofi
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Johnson & Johnson Services, Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Panacea Biotec Limited
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Astellas Pharma Inc.
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 NOVAVAX, INC.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 VBI Vaccines Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Bavarian Nordic.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Get Free Sample For North America Vaccines Market
